Rigel Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Rigel Pharmaceuticals şirketinin toplam hissedar öz sermayesi $-29.9M ve toplam borcu $99.7M olup, bu da borç-öz sermaye oranını -333.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $128.4M ve $158.3M dir.

Anahtar bilgiler

-333.2%

Borç/özkaynak oranı

US$99.67m

Borç

Faiz karşılama oranı	n/a
Nakit	US$49.10m
Eşitlik	-US$29.91m
Toplam yükümlülükler	US$158.32m
Toplam varlıklar	US$128.41m

Son finansal sağlık güncellemeleri

Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Apr 21

Recent updates

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15

What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Mar 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RIGL negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: RIGL şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RIGL negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: RIGL 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RIGL şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: RIGL tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Rigel Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Recent updates

Rigel Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Price target increased by 34% to US$26.75

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2024

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$0.43 loss

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application

Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress

Insufficient new directors

Consensus EPS estimates upgraded to US$0.062 loss

Consensus EPS estimates upgraded to US$0.073 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target increased by 14% to US$5.08

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Consensus EPS estimates fall by 13%

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

President recently sold US$60k worth of stock

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

No longer forecast to breakeven

New minor risk - Share price stability

Forecast to breakeven in 2025

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Consensus EPS estimates upgraded to US$0.19 loss

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial

Consensus EPS estimates upgraded to US$0.25 loss

New minor risk - Profitability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Price target increased by 7.6% to US$3.85

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

Rigel Pharmaceuticals, Inc. Announces Publication of REZLIDHIA (Olutasidenib) Phase 2 Clinical Results in Blood Advances

National Comprehensive Cancer Network Adds Newly Approved Rigel Pharmaceuticals, Inc.'s REZLIDHIA™ (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

Price target increased to US$4.11

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Rigel Pharmaceuticals, Inc. Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals, Inc. Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Rigel Pharmaceuticals, Inc. Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Rigel Pharmaceuticals, Inc. Announces Publication of Early Clinical Data of Olutasidenib in the Lancet Haematology

Third quarter 2022 earnings: EPS exceeds analyst expectations

Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Focus Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized Covid-19 Patients

Rigel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Now 22% undervalued after recent price drop

Rigel Pharmaceuticals, Inc. Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib

Now 21% undervalued